NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine | Biotech Hunter

Enrollment

244

Participants

Timeline

Start Date

September 19, 2020

Primary Completion Date

November 25, 2020

Study Completion Date

April 25, 2021

Conditions

Covid19SARS-CoV InfectionVaccine Adverse Reaction

Interventions

BIOLOGICAL

QazCovid-in® - COVID-19 inactivated vaccine

QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

OTHER

Placebo

Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)

Trial Locations (1)

080409

Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy

All Listed Sponsors

collaborator

National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan

UNKNOWN

lead

Research Institute for Biological Safety Problems

OTHER_GOV